News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,688 Results
Type
Article (14902)
Company Profile (299)
Press Release (266481)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79835)
Career Advice (162)
Deals (13337)
Drug Delivery (39)
Drug Development (50702)
Employer Resources (31)
FDA (5837)
Job Trends (5167)
News (145079)
Policy (10071)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (19)
Adcomms (14)
Allergies (82)
Alliances (21761)
ALS (126)
Alzheimer's disease (1032)
Antibody-drug conjugate (ADC) (242)
Approvals (6031)
Artificial intelligence (262)
Autoimmune disease (115)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (345)
Cancer (3138)
Cardiovascular disease (238)
Career advice (147)
Career pathing (7)
CAR-T (221)
CDC (5)
Cell therapy (568)
Cervical cancer (14)
Clinical research (43690)
Collaboration (1157)
Company closure (2)
Compensation (597)
Complete response letters (40)
COVID-19 (1101)
CRISPR (86)
C-suite (559)
Cystic fibrosis (112)
Data (4339)
Denatured (15)
Depression (93)
Diabetes (255)
Diagnostics (1380)
Digital health (11)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (193)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (216)
Earnings (31649)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51680)
Executive appointments (625)
FDA (7595)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (989)
Gene editing (182)
Generative AI (22)
Gene therapy (492)
GLP-1 (506)
Government (1148)
Grass and pollen (3)
Guidances (166)
Healthcare (6611)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (192)
Immuno-oncology (42)
Indications (66)
Infectious disease (1206)
Inflammatory bowel disease (156)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7346)
IRA (12)
Job creations (867)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1400)
Liver cancer (41)
Longevity (11)
Lung cancer (423)
Lymphoma (250)
Machine learning (24)
Management (7)
Manufacturing (377)
MASH (130)
Medical device (2663)
Medtech (2672)
Mergers & acquisitions (6618)
Metabolic disorders (729)
Multiple sclerosis (104)
NASH (13)
Neurodegenerative disease (233)
Neuropsychiatric disorders (70)
Neuroscience (1958)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (865)
Now hiring (30)
Obesity (332)
Opinion (125)
Ovarian cancer (132)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (334)
Peanut (43)
People (26667)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15480)
Phase 2 (20302)
Phase 3 (12823)
Pipeline (3289)
Policy (90)
Postmarket research (853)
Preclinical (6536)
Press Release (30)
Prostate cancer (146)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (655)
Real estate (1448)
Recruiting (12)
Regulatory (9905)
Reports (19)
Research institute (972)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (183)
Series B (140)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2006)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (336)
Venture capital (69)
Weight loss (174)
Women's health (26)
Worklife (2)
Date
Today (72)
Last 7 days (350)
Last 30 days (1240)
Last 365 days (17862)
2026 (1777)
2025 (18098)
2024 (20543)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18260)
Australia (3111)
California (7096)
Canada (1843)
China (777)
Colorado (248)
Connecticut (252)
Delaware (236)
Europe (39187)
Florida (905)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (36)
Indiana (161)
Iowa (8)
Japan (225)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5601)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1649)
New Mexico (13)
New York (1768)
North Carolina (831)
North Dakota (6)
Northern California (3488)
Ohio (179)
Oklahoma (11)
Oregon (24)
Pennsylvania (1282)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2814)
Tennessee (40)
Texas (910)
United States (23402)
Utah (97)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (46)
281,688 Results for "lycia therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Lycia Therapeutics Completes $106.6 Million Series C Financing to Advance Pipeline of LYTAC Extracellular Protein Degraders to the Clinic
Lycia Therapeutics, Inc., a leader in extracellular protein degradation, announced the completion of an oversubscribed $106.6 million Series C financing.
May 13, 2024
·
3 min read
Business
Nona Biosciences Announces Collaboration Agreement with Lycia Therapeutics
Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, announced it has entered into a collaboration agreement with Lycia Therapeutics, a leader in extracellular protein degradation.
December 4, 2023
·
2 min read
Press Releases
Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline
February 11, 2025
·
5 min read
Biotech Bay
Lycia Therapeutics to Present at Jefferies 2023 Healthcare Conference
Lycia Therapeutics, Inc., a leader in extracellular protein degradation, announced that Aetna Wun Trombley, Ph.D., President and Chief Executive Officer of Lycia, will present a corporate overview at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 2:00 pm ET in New York.
June 5, 2023
·
1 min read
Business
Lycia Therapeutics Founder Dr. Carolyn Bertozzi Awarded 2022 Nobel Prize in Chemistry
Lycia Therapeutics, Inc. announced that founder Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in Chemistry.
October 5, 2022
·
2 min read
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
Business
Lycia Therapeutics Strengthens Leadership Team with Appointment of Steve Staben, Ph.D. as Chief Scientific Officer
Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced the recent appointment of Steve Staben, Ph.D., as Chief Scientific Officer.
February 28, 2022
·
3 min read
Business
Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders
Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia’s proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology.
August 25, 2021
·
4 min read
Biotech Bay
Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Ventures
Lycia Therapeutics, Inc. today announced the completion of an oversubscribed $70 million Series B financing.
September 9, 2021
·
3 min read
Press Releases
Altamira Therapeutics to Present at mRNA-Based Therapeutics Summit
January 26, 2026
·
4 min read
1 of 28,169
Next
